Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for IL18RAP drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IL18RAP ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View IL18RAP Products |
| Gene Delivery | IL18RAP Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. Ideal for maintaining native conformation in cell-based assays. |
View IL18RAP Products |
| Benchmark Ab | Anti-IL18RAP Recombinant Antibody Recombinant positive control derived from public clinical sequences. Sequence verified. |
View IL18RAP Products |
| Validator | IL18RAP siRNA Set For knockdown verification and target specificity validation. |
View IL18RAP Products |
| Related Target A | IL18R1 The primary binding subunit of the heterodimeric IL-18 receptor complex. Co-expression or co-incubation is required for functional signaling assays. |
View IL18R1 Products |
| Related Target B | IL18 The native pro-inflammatory cytokine ligand that initiates signaling through the IL18R1/IL18RAP complex. |
View IL18 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Reconstituting the Heterodimeric Signaling Complex | High-purity, HEK293-expressed IL18R1 and IL18RAP ECD-Fc proteins with native glycosylation patterns to mimic physiological assembly. |
| Cross-species Cynomolgus/Mouse Cross-reactivity Screening | Ortholog recombinant proteins (Human, Cynomolgus, Mouse) strictly verified by mass spectrometry and sequence analysis. |
| Lack of Validated Screening Controls | Clinical Benchmark Antibodies (Biosimilars) and sequence-verified positive controls included. |
| Off-Target and False Positive Verification | Highly specific siRNA knockdown sets and homolog panels (IL1RL1/ST2, IL1R1) to rule out non-specific binding. |
Live IL18RAP/CD218b R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IL18RAP therapeutics is intensifying, with major players shifting focus from traditional systemic cytokine blockade to targeted monoclonal antibodies (mAbs) and bispecific constructs that modulate the IL-18/IL-18R axis. As first-generation systemic IL-18 therapies faced limitations due to binding proteins (IL-18BP) and off-target toxicities, the next wave of R&D is targeting the receptor accessory protein IL18RAP to selectively block or enhance signal transduction in specific disease microenvironments.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (Antagonist) | Academic Institutes, Biopharma Consortiums | Inflammatory Bowel Disease (IBD), Crohn's, Celiac Disease | Ligand-blocking screening (Requires high-purity IL18RAP and IL18R1 ECD-Fc to assay disruption of the ternary complex) |
| Bispecific Antibody / Cytokine Fusion | Innovative Biotech Startups | Solid Tumors, Autoimmune Disorders | Heterodimer validation and dual-targeting affinity measurements (Requires cross-reactive ortholog proteins) |
| Small Molecule Inhibitors | Global Pharmaceutical Companies | Refractory Autoimmune Conditions | Selectivity assays against related IL-1 receptor family members (Requires homolog panel proteins) |